Last updated: August 9, 2026
Voltaren is primarily a diclofenac topical brand, with products that differ by jurisdiction, dosage form, concentration, salt form, and regulatory status. The largest commercial opportunity is in improved topical diclofenac delivery: lower residue, faster drying, better skin tolerability, dose metering, preservative reduction, and differentiated delivery systems. The core active ingredient is generic and heavily competed, so commercial value is more likely to come from excipient selection, device integration, clinical usability, and regulatory positioning than from diclofenac itself.
What is Voltaren and which formulations are commercially relevant?
Voltaren products contain diclofenac, a nonsteroidal anti-inflammatory drug used for pain and inflammation. The principal topical U.S. product is Voltaren Arthritis Pain, a 1% diclofenac sodium topical gel indicated for temporary relief of arthritis pain in certain joints. The product was switched from prescription to nonprescription status in the United States in 2020.[1]
Voltaren-branded products vary internationally. They include topical gels, emulsions, creams, sprays, patches, oral products, and ophthalmic products. The formulation strategy and competitive landscape depend on the specific product.
| Product category |
Typical active ingredient |
Primary formulation issue |
Commercial relevance |
| U.S. Voltaren Arthritis Pain |
Diclofenac sodium 1% |
Gel performance, skin feel, dose accuracy |
Largest consumer-facing U.S. opportunity |
| Prescription diclofenac gel |
Diclofenac sodium 1% |
Therapeutic equivalence and labeling |
Generic competition and payer substitution |
| International Voltaren Emulgel |
Often diclofenac diethylamine |
Emulsion structure, salt selection, absorption |
Regional formulation and trademark opportunity |
| Diclofenac topical solution |
Diclofenac sodium, commonly 1.5% or 2% |
Solvent system and spreading |
Niche, prescription-oriented opportunity |
| Diclofenac patches or plasters |
Diclofenac salt or free-acid form |
Adhesion, release, wear time |
Differentiation through delivery device |
| Oral or ophthalmic Voltaren |
Product-specific diclofenac form |
Route-specific tolerability and stability |
Separate regulatory and patent analysis |
The U.S. Voltaren Arthritis Pain label identifies diclofenac sodium as the active ingredient and lists a conventional semisolid excipient system containing carbomer, propylene glycol, isopropyl alcohol, mineral oil, a surfactant, water, and other formulation components.[2]
What excipients are used in Voltaren topical gel?
The U.S. product uses a carbomer-based gel with co-solvents, emollient components, a surfactant, alcohol, and water. The excipient system performs several functions:
| Excipient or excipient class |
Likely formulation function |
| Carbomer homopolymer |
Viscosity, gel structure, suspension stability |
| Propylene glycol |
Co-solvent, humectant, skin penetration support |
| Isopropyl alcohol |
Volatile solvent, rapid-drying contribution, sensory effect |
| Mineral oil |
Emolliency and skin feel |
| Cocoyl caprylocaprate |
Emollient and spreading modifier |
| Polyoxyl 20 cetostearyl ether |
Emulsification and phase stabilization |
| Purified water |
Continuous phase and vehicle |
| Fragrance |
Consumer acceptability, although it can create sensitization concerns |
The formulation is designed to balance four competing requirements:
- Maintain diclofenac solubility and uniformity.
- Permit the product to spread over a joint.
- Deliver diclofenac through the skin.
- Dry or absorb without unacceptable tack, residue, or odor.
Carbomer concentration, neutralization, polymer grade, alcohol level, and oil-phase composition can materially alter viscosity, drug release, skin permeation, drying time, and user acceptance. These parameters are potential sources of formulation know-how even when the ingredient list itself is not novel.
How does Voltaren’s excipient strategy affect product performance?
The principal technical challenge is achieving meaningful local diclofenac exposure without creating a product that consumers reject because it is greasy, sticky, slow to dry, or irritating.
Viscosity and spreadability
Carbomer provides a structured gel that keeps diclofenac distributed and allows application to knees, hands, elbows, ankles, and other joints. Excessive viscosity can reduce spreadability and increase the amount users apply. Insufficient viscosity can cause runoff, phase separation, poor dose uniformity, and packaging leakage.
A commercial formulation program should test:
- Yield stress and shear-thinning behavior
- Spread area per gram
- Residue after drying
- Drug uniformity during storage
- Viscosity changes across temperature
- Compatibility with tubes, pumps, and dose-metering devices
Skin penetration and solvent balance
Propylene glycol and alcohol can support diclofenac solubilization and dermal delivery. Higher solvent levels may improve release but can increase stinging, dryness, odor, or volatility. Oil-phase components can improve skin feel but may slow drying or leave residue.
The commercial objective is not maximum permeation in isolation. It is a controlled balance between permeation, local retention, systemic exposure, and user adherence.
Fragrance and sensitization
Fragrance can improve acceptability by masking the odor of solvents or active ingredients. It can also create a regulatory and consumer-risk issue for users with fragrance sensitivity. A fragrance-free Voltaren-compatible product could target patients who discontinue topical NSAIDs because of odor or skin discomfort.
Preservative strategy
An aqueous gel requires microbial control, but the platform may be designed to reduce preservative dependence through:
- Lower water activity
- Alcohol-containing systems
- Airless packaging
- Single-dose sachets
- Improved manufacturing controls
- Preservative systems with lower irritation potential
A preservative-free claim requires a product-specific microbiological control strategy and stability package. It cannot be inferred from the absence of a conventional preservative on an ingredient list.
What formulation patents protect Voltaren-type products?
Voltaren-type products may be protected by several types of intellectual property, although the commercial strength of each category varies.
Composition-of-matter and salt patents
Diclofenac itself is old and broadly generic. Basic composition-of-matter protection is not a meaningful barrier for current topical competitors. Salt selection, such as diclofenac sodium versus diclofenac diethylamine, may affect formulation properties but generally does not create a durable barrier without a specific, enforceable claim.
Formulation patents
Potential formulation claims can cover:
- Specific carbomer grades or polymer combinations
- Defined diclofenac concentration ranges
- Alcohol and glycol ratios
- Emulsion phase ratios
- Particle size or droplet size
- pH ranges
- Viscosity windows
- Release or permeation profiles
- Low-residue or rapid-drying compositions
- Preservative-free systems
- Enhanced skin penetration systems
A formulation patent is commercially stronger when its claims require measurable product attributes that are difficult to design around. Claims limited to a list of common excipients are usually more vulnerable to substitution.
Method-of-use patents
Topical diclofenac products may be associated with claims covering treatment of osteoarthritis pain, specific joints, dosing frequency, or application regimens. In the U.S., method-of-use claims can affect generic labeling and Paragraph IV litigation, but their practical value depends on the scope of approved labeling and the ability to remove the patented indication from a generic label.
Manufacturing and process protection
Manufacturing know-how may cover:
- Carbomer dispersion and hydration
- Neutralization sequence
- Mixing shear
- Temperature control
- Deaeration
- Emulsion particle-size control
- Filling and sealing
- Bulk hold times
- Tube compatibility
These controls may be protected as trade secrets rather than patents. For topical semisolids, process conditions can affect performance enough to create a meaningful quality and scale-up barrier.
What is the FDA and Orange Book status of Voltaren?
Voltaren Arthritis Pain is an FDA-approved nonprescription topical diclofenac sodium gel product. The U.S. approval followed a prescription-to-OTC switch for temporary relief of arthritis pain in adults.[1]
The Orange Book is relevant primarily to approved prescription drug products and their listed patents or exclusivity. OTC switch products may have a different listing profile from prescription Voltaren products, and the regulatory status of a particular NDA, supplement, or discontinued prescription presentation must be checked in the current FDA databases.[3]
For competitive diligence, analysts should distinguish:
| Regulatory issue |
Why it matters |
| OTC monograph eligibility |
Determines whether a new product can avoid an NDA |
| NDA or ANDA pathway |
Determines approval requirements and patent certifications |
| Therapeutic equivalence |
Critical for prescription generic substitution |
| Labeling scope |
Determines whether indications can be carved out |
| Product-specific guidance |
May define comparative clinical or in vitro requirements |
| OTC switch history |
Affects consumer labeling, advertising, and distribution |
A new diclofenac gel using the same active ingredient may require an ANDA if it qualifies as a therapeutically equivalent generic to an approved reference product. A materially different dosage form, delivery system, concentration, or indication may require an NDA or another 505(b)(2) strategy.
When does Voltaren lose exclusivity and what generic entry risks exist?
The original protection for diclofenac and early Voltaren formulations has expired. Current market barriers are therefore based on regulatory complexity, brand recognition, formulation performance, device differentiation, retailer access, and consumer trust.
Generic entry risk is high for conventional diclofenac gels. The main threats include:
- Low-cost private-label and pharmacy-brand gels
- International manufacturers with existing topical capacity
- Prescription-to-OTC substitution
- Retailer-owned brands
- Online channel price competition
- Alternate diclofenac concentrations and dosage forms
A generic competitor does not need to reproduce every excipient in Voltaren. It generally needs to satisfy the applicable regulatory requirements for sameness, equivalence, performance, stability, and labeling. Excipients can be changed if the resulting product remains acceptable under the relevant approval pathway.
What makes generic substitution difficult?
Topical semisolids are more complex than conventional immediate-release tablets. Performance depends on the formulation microstructure, not only on the active ingredient and nominal concentration. Relevant tests can include:
- In vitro release testing
- In vitro permeation testing
- Rheology
- Globule or particle-size distribution
- pH
- Drug content uniformity
- Adhesion and spreading
- Stability under accelerated and long-term conditions
FDA guidance for topical products recognizes that formulation sameness and performance may require more than a simple ingredient comparison.[4]
Which excipient-led commercial opportunities are most attractive?
Fragrance-free and sensitive-skin products
A fragrance-free product can target consumers with contact sensitivity or a preference for neutral-smelling products. The opportunity is strongest if the product retains acceptable drying, spreadability, and skin feel without relying on fragrance to mask solvent odor.
Fast-drying, low-residue gel
A low-residue system could differentiate from conventional carbomer gels. Candidate approaches include lower-oil emulsions, volatile solvent optimization, lightweight esters, silicone-compatible emollients, and rheology modifiers that provide initial structure but collapse quickly under shear.
The key claim must be supported by objective testing. “Fast-drying” and “non-greasy” are commercially useful only when linked to defined test methods and consumer data.
Metered-dose delivery
A pump, airless dispenser, or dose-metering applicator can improve dose consistency and reduce contamination. It may also support a product-level patent around:
- Defined actuation volume
- Dose-lock mechanism
- Inversion-independent delivery
- Airless preservation
- Applicator geometry
- Controlled application to irregular joints
Packaging can create a stronger practical barrier than a modest excipient variation because it combines formulation, device, and user-interface claims.
Hydroalcoholic or foam systems
A foam or rapidly evaporating hydroalcoholic product could improve application speed and reduce residue. The main risks are skin irritation, flammability controls, aerosol or propellant regulation, and maintaining diclofenac uniformity during storage.
Patch and film systems
Diclofenac patches offer a longer-wear alternative to gel. Opportunities include thin flexible films, hydrogel patches, microneedle-assisted delivery, and adhesive systems designed for knees and hands. The regulatory burden is higher because the product must demonstrate reliable drug delivery, adhesion, wear performance, and skin tolerability.
Barrier-repair and tolerability positioning
A formulation incorporating skin-conditioning components could target chronic users who experience dryness or irritation. The developer must control the risk that additional excipients reduce diclofenac release, increase systemic exposure, or complicate the nonprescription label.
How does Voltaren compare with competing topical diclofenac products?
| Attribute |
Conventional Voltaren-type gel |
Diclofenac solution |
Diclofenac patch |
Cream or emulsion |
| User familiarity |
High |
Moderate |
Moderate |
Moderate |
| Manufacturing complexity |
Moderate |
Moderate |
High |
Moderate |
| Dose consistency |
Variable with hand application |
Variable |
Potentially high |
Variable |
| Residue risk |
Moderate |
Low to moderate |
Low after removal |
Moderate to high |
| Differentiation potential |
Limited through excipients |
Moderate |
High |
Moderate |
| Regulatory complexity |
Established |
Established but product-specific |
Higher |
Established |
| IP opportunity |
Formulation and device |
Solvent and delivery system |
Adhesive, film, release |
Emulsion and skin-feel claims |
Voltaren’s strongest commercial advantage is brand recognition. Its weakness is that conventional topical gel is relatively easy to approach with generic products. A challenger is more likely to win through superior usability than through a small change in diclofenac concentration.
What licensing opportunities exist around Voltaren-type excipients?
Licensing opportunities are most credible in four areas:
- Proprietary dermal penetration technologies with human data.
- Airless or metered-dose packaging systems.
- Low-irritation preservative or antimicrobial systems.
- Film, patch, or foam platforms with demonstrated diclofenac delivery.
A licensee should prioritize technologies that already have:
- Human dermal safety data
- Compatibility with diclofenac salts
- Commercial manufacturing at relevant scale
- Stability data in the intended package
- Freedom-to-operate analysis
- A clear regulatory pathway
A generic excipient supplier relationship is less likely to create durable differentiation unless the supplier has a proprietary grade, technical package, or exclusive supply arrangement.
What patent litigation and settlement risks affect diclofenac topical products?
The principal litigation risk for a new topical diclofenac product is not usually a basic active-ingredient patent. It is the combination of formulation patents, device claims, manufacturing claims, and method-of-use claims.
For an ANDA applicant, Paragraph IV risk depends on current Orange Book listings for the relevant reference product. For an OTC or NDA product, risk may instead arise from non-Orange Book patents, trade dress, trademark rights, unfair competition claims, or patents covering a delivery device or formulation technology.
Settlement agreements may include delayed launch dates, licenses, authorized generic arrangements, or restrictions on product labeling. Their commercial value depends on the precise patent claims and the settlement terms. A patent landscape should separate expired patents from live patents and distinguish listed patents from non-listed technology rights.
How strong is the Voltaren excipient patent estate?
The base excipient estate for a conventional diclofenac gel is likely to be moderate to weak against routine formulation design-around because common carbomers, glycols, alcohols, oils, surfactants, and water are widely available. Strength increases when protection covers a specific combination tied to a measurable performance result or an integrated package-and-formulation system.
| IP category |
Expected defensive value |
| Basic diclofenac composition |
Low |
| Common excipient list |
Low to moderate |
| Defined rheology or release profile |
Moderate |
| Novel penetration technology |
Moderate to high |
| Metered-dose device |
Moderate to high |
| Manufacturing process know-how |
High as trade secret, if difficult to reverse engineer |
| Brand and trade dress |
High for consumer products, separate from formulation IP |
Key Takeaways
- Voltaren’s main U.S. commercial product is diclofenac sodium 1% topical gel.
- Its excipient platform combines carbomer gel structure, glycols, alcohol, oil-phase components, surfactant, and water.
- Conventional diclofenac gel has high generic-entry risk because the active ingredient and basic formulation technology are mature.
- The strongest commercial opportunities are fragrance-free products, low-residue gels, metered-dose packaging, airless systems, foams, and patches.
- Formulation patents are most valuable when they claim measurable performance or integrated device and formulation features.
- OTC status, NDA or ANDA pathway, Orange Book listings, and product-specific FDA requirements determine the regulatory strategy.
- Manufacturing controls and packaging compatibility can create practical barriers even where composition patents are weak.
- Licensing value is highest for dermal delivery technologies supported by human data and scalable manufacturing.
FAQs About Voltaren Excipient Strategy and Commercialization
Can a competitor use different excipients from Voltaren?
Yes. A competitor may use a different excipient system if the product meets the applicable FDA requirements for its regulatory pathway, including quality, stability, performance, safety, and labeling requirements.
Is carbomer essential to a diclofenac topical gel?
No. Carbomer is widely used because it provides useful viscosity and gel structure, but alternative polymers, emulsions, creams, foams, and film-forming systems can deliver diclofenac through different formulation platforms.
Is a preservative-free Voltaren-type product commercially feasible?
Yes, but the product requires a validated microbiological control strategy. Airless packaging, reduced water activity, single-use packaging, or a different solvent system may support the strategy.
Can packaging create patent protection for a diclofenac gel?
Yes. Claims may cover dose metering, airless dispensing, applicator geometry, package orientation, contamination control, or integration between the package and the formulation.
Are biosimilar risks relevant to Voltaren?
No. Diclofenac is a small-molecule drug, so the relevant competitive threats are generic drugs, authorized generics, OTC private-label products, and alternative topical delivery systems rather than biosimilars.
References
- U.S. Food and Drug Administration. (2020). FDA approves first over-the-counter topical diclofenac gel for arthritis pain. https://www.fda.gov
- DailyMed. (n.d.). Voltaren Arthritis Pain diclofenac sodium topical gel, 1%: Drug label. National Library of Medicine. https://dailymed.nlm.nih.gov
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
- U.S. Food and Drug Administration. (2022). Physicochemical and structural (Q3) characterization of topical drug products submitted in ANDAs. https://www.fda.gov
